The most common location of a hydatid cyst (HC) is the liver, followed by the lungs and other organs. Hydatid cysts in the anterior chest wall are an exceedingly rare complication and much rarer if it is associated with liver HC. A 53-year-old man presented to our clinic with a painless anterior chest wall mass (ACWM). Thoraco-abdominal computed tomography revealed simple cystic masses localized in the ACWM in subcutaneous tissue with no invasion of the peripheral soft tissue and no pulmonary or rib involvement. An echinococcal indirect hemagglutination test was negative. Dermoid cyst was considered as a diagnosis and the encapsulated masses were dissected through its plane in peripheral tissue adhesion and removed completely. Macroscopic and microscopic examination of the specimens confirmed hydatid cysts. Further organ evaluation revealed the liver hydatid cyst. The patient was referred for surgery where he underwent laparotomy and drainage of cyst content and capitonaged into peritoneal cavity. This case report demonstrates that hydatid cysts should be considered as a possible cause for palpable lesions in the chest wall, especially in endemic locations.
{"title":"Combined chest wall and liver hydatid cyst","authors":"Feridoun Sabzi, Reza Faraji","doi":"10.21542/gcsp.2023.32","DOIUrl":"https://doi.org/10.21542/gcsp.2023.32","url":null,"abstract":"The most common location of a hydatid cyst (HC) is the liver, followed by the lungs and other organs. Hydatid cysts in the anterior chest wall are an exceedingly rare complication and much rarer if it is associated with liver HC. A 53-year-old man presented to our clinic with a painless anterior chest wall mass (ACWM). Thoraco-abdominal computed tomography revealed simple cystic masses localized in the ACWM in subcutaneous tissue with no invasion of the peripheral soft tissue and no pulmonary or rib involvement. An echinococcal indirect hemagglutination test was negative. Dermoid cyst was considered as a diagnosis and the encapsulated masses were dissected through its plane in peripheral tissue adhesion and removed completely. Macroscopic and microscopic examination of the specimens confirmed hydatid cysts. Further organ evaluation revealed the liver hydatid cyst. The patient was referred for surgery where he underwent laparotomy and drainage of cyst content and capitonaged into peritoneal cavity. This case report demonstrates that hydatid cysts should be considered as a possible cause for palpable lesions in the chest wall, especially in endemic locations.","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136072886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpha-gal syndrome (AGS) refers to a potentially life-threatening allergy to the molecule galactose-α1,3-galactose (gal), which is expressed on most mammalian tissues but, importantly, is not expressed by humans. This syndrome can manifest as an allergic reaction to mammalian meat products, but other sources of mammalian tissue can also provoke an immune response, including injectable and implantable medical products. This syndrome has been linked to coronary atherosclerosis, and medical products that express gal are routinely used in cardiology and cardiac surgery. This article seeks to discuss potential implications of alpha syndrome as it relates to cardiovascular health and to heighten awareness in the cardiovascular community about this emerging public health issue.
{"title":"Alpha-gal syndrome: Implications for cardiovascular disease","authors":"J. Bianchi, A. Walters, Z. Fitch, J. Turek","doi":"10.21542/gcsp.2019.20","DOIUrl":"https://doi.org/10.21542/gcsp.2019.20","url":null,"abstract":"Alpha-gal syndrome (AGS) refers to a potentially life-threatening allergy to the molecule galactose-α1,3-galactose (gal), which is expressed on most mammalian tissues but, importantly, is not expressed by humans. This syndrome can manifest as an allergic reaction to mammalian meat products, but other sources of mammalian tissue can also provoke an immune response, including injectable and implantable medical products. This syndrome has been linked to coronary atherosclerosis, and medical products that express gal are routinely used in cardiology and cardiac surgery. This article seeks to discuss potential implications of alpha syndrome as it relates to cardiovascular health and to heighten awareness in the cardiovascular community about this emerging public health issue.","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117057817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Yacoub, M. Nagy, Hatem Hosny, R. Doss, A. Afifi, A. Guindy, S. Romeih, H. Aguib
Crypts are very thin walled invaginations from the cavity of the left ventricle into the compact myocardium. With the advent and increased application of multimodality imaging, crypts are being increasingly identified in both normal individuals and patients, with various conditions including HCM, before and after the development of LV hypertrophy, LV non-compaction and hypertensive heart disease. to date crypts have not been described in the right ventricle. We here describe for the first time, RV crypts which were extending into a myocardial bridge, in a patient with HCM and dynamic obstruction of the LAD coronary artery. We also document and discuss the serious complications which can arise from crypts, and highlight the importance of preoperative identification of crypts. Further studies are required to determine the fetal origin of crypts and their clinical significance
{"title":"Right ventricular crypts in a myocardial bridge: Relevance to surgical relief","authors":"M. Yacoub, M. Nagy, Hatem Hosny, R. Doss, A. Afifi, A. Guindy, S. Romeih, H. Aguib","doi":"10.21542/gcsp.2019.21","DOIUrl":"https://doi.org/10.21542/gcsp.2019.21","url":null,"abstract":"Crypts are very thin walled invaginations from the cavity of the left ventricle into the compact myocardium. With the advent and increased application of multimodality imaging, crypts are being increasingly identified in both normal individuals and patients, with various conditions including HCM, before and after the development of LV hypertrophy, LV non-compaction and hypertensive heart disease. to date crypts have not been described in the right ventricle. We here describe for the first time, RV crypts which were extending into a myocardial bridge, in a patient with HCM and dynamic obstruction of the LAD coronary artery. We also document and discuss the serious complications which can arise from crypts, and highlight the importance of preoperative identification of crypts. Further studies are required to determine the fetal origin of crypts and their clinical significance","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"98 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131994743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Ramirez, Christopher A. Thomas, Ryan J. Anderson, R. Bernardo, A. Al‐Motarreb, J. Al-Suwaidi, R. Zamanian, V. D. Perez
Drug- and toxin-induced pulmonary arterial hypertension (PAH) is an increasingly important sub-group of group 1 pulmonary hypertension (PH). In the last 60 years, we have seen the rise and fall of numerous prescription and illicit agents that have caused severe and deadly outbreaks of PAH. Currently, drugs and toxins are classified into “possible” and “definite” risk factors for PAH. While the exact mechanisms and pathogenesis of drug- and toxin-induced PAH are currently unknown, novel clinical and basic science studies are beginning to unravel the biologic factors and genetic underpinnings responsible for disease development. The clinical management of affected patients can be challenging as it is often difficult to identify patients early and demonstrate causality between drugs and PAH. Given the recent trends in drug utilization and development, it is highly likely that we will continue to identify new agents capable of causing pulmonary vascular disease. We must keep a high index of suspicion in order to identify patients and new compounds deemed definite or likely risk factors for PAH. Practicing pharmacovigilance, raising awareness, and working in tandem with PH patient associations and drug regulatory agencies may ultimately be our most effective strategy in preventing the next deadly outbreak of drug- and toxin-induced PAH.
{"title":"Drug- and toxin-induced pulmonary arterial hypertension: Current state of the literature","authors":"R. Ramirez, Christopher A. Thomas, Ryan J. Anderson, R. Bernardo, A. Al‐Motarreb, J. Al-Suwaidi, R. Zamanian, V. D. Perez","doi":"10.21542/gcsp.2019.19","DOIUrl":"https://doi.org/10.21542/gcsp.2019.19","url":null,"abstract":"Drug- and toxin-induced pulmonary arterial hypertension (PAH) is an increasingly important sub-group of group 1 pulmonary hypertension (PH). In the last 60 years, we have seen the rise and fall of numerous prescription and illicit agents that have caused severe and deadly outbreaks of PAH. Currently, drugs and toxins are classified into “possible” and “definite” risk factors for PAH. While the exact mechanisms and pathogenesis of drug- and toxin-induced PAH are currently unknown, novel clinical and basic science studies are beginning to unravel the biologic factors and genetic underpinnings responsible for disease development. The clinical management of affected patients can be challenging as it is often difficult to identify patients early and demonstrate causality between drugs and PAH. Given the recent trends in drug utilization and development, it is highly likely that we will continue to identify new agents capable of causing pulmonary vascular disease. We must keep a high index of suspicion in order to identify patients and new compounds deemed definite or likely risk factors for PAH. Practicing pharmacovigilance, raising awareness, and working in tandem with PH patient associations and drug regulatory agencies may ultimately be our most effective strategy in preventing the next deadly outbreak of drug- and toxin-induced PAH.","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122831946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Quarta, A. Iacovoni, C. Marrone, A. Grosu, P. Brambilla, I. Olivotto, A. Gavazzi, M. Senni
An 11-year old boy was admitted to our intensive care unit following a successfully resuscitated ventricular fibrillation (VF) cardiac arrest during mild physical activity. Six months earlier he was diagnosed with non-obstructive hypertrophic cardiomyopathy (HCM) after an ECG at a pre-sport participating screening had shown left ventricular hypertrophy, marked repolarization abnormalities, and ST depression (Figure 1). There was no family history of HCM or sudden cardiac death (SCD). The child had been completely asymptomatic before the event; specifically, he had never experienced syncopal episodes. Maximal left ventricular wall thickness on echocardiography was 18 mm (z-score 4,5) and an Echo-bike and a 24h Holter monitor had been completely unremarkable. He was on no medications.
一名11岁男孩在轻度体力活动期间心室颤动(VF)心脏骤停成功复苏后被送入我们的重症监护室。6个月前，他被诊断为非阻塞性肥厚性心肌病(HCM)，在运动前参与筛查的心电图显示左心室肥厚、明显的复极异常和ST段抑制(图1)。他没有HCM或心源性猝死(SCD)的家族史。该儿童在事件发生前完全无症状;具体来说，他从未经历过晕厥发作。超声心动图显示的最大左室壁厚度为18 mm (z-score 4,5)，超声自行车和24小时动态心电图完全没有明显变化。他没有吃药。
{"title":"Microvascular ischaemia after cardiac arrest in a patient with hypertrophic cardiomyopathy","authors":"G. Quarta, A. Iacovoni, C. Marrone, A. Grosu, P. Brambilla, I. Olivotto, A. Gavazzi, M. Senni","doi":"10.5339/GCSP.2015.51","DOIUrl":"https://doi.org/10.5339/GCSP.2015.51","url":null,"abstract":"An 11-year old boy was admitted to our intensive care unit following a successfully resuscitated ventricular fibrillation (VF) cardiac arrest during mild physical activity. Six months earlier he was diagnosed with non-obstructive hypertrophic cardiomyopathy (HCM) after an ECG at a pre-sport participating screening had shown left ventricular hypertrophy, marked repolarization abnormalities, and ST depression (Figure 1). There was no family history of HCM or sudden cardiac death (SCD). The child had been completely asymptomatic before the event; specifically, he had never experienced syncopal episodes. Maximal left ventricular wall thickness on echocardiography was 18 mm (z-score 4,5) and an Echo-bike and a 24h Holter monitor had been completely unremarkable. He was on no medications.","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126080388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Microparticles, in the context of this review, are defined as plasma membrane derived-particles shed by various types of vascular and blood cells in response to different stimuli. They were first described as products of platelet activation or “platelet dust”, however microparticles are now ascribed prominent roles in cardiovascular diseases and contribute to the regulation of pathophysiological processes including, endothelial function, inflammation, coagulation, angiogenesis, and cellular remodelling. Furthermore, microparticles serve as cell-cell messengers by transfer of biological information to target cells in pathophysiological settings and have proven to be prominent biomarkers for health and physiology assessments for both diagnostic and risk stratification purposes. This review describes the mechanisms of microparticles formation, release and clearance, and their detection by currently available and applicable methods. It also discusses the role of microparticles in the development of cardiovascular diseases, as well as their role as biomarkers and cell effectors in the cardiovascular system.
{"title":"Microparticles: Biomarkers and effectors in the cardiovascular system","authors":"H. A. Saleh, B. Kabeer","doi":"10.5339/GCSP.2015.38","DOIUrl":"https://doi.org/10.5339/GCSP.2015.38","url":null,"abstract":"Microparticles, in the context of this review, are defined as plasma membrane derived-particles shed by various types of vascular and blood cells in response to different stimuli. They were first described as products of platelet activation or “platelet dust”, however microparticles are now ascribed prominent roles in cardiovascular diseases and contribute to the regulation of pathophysiological processes including, endothelial function, inflammation, coagulation, angiogenesis, and cellular remodelling. Furthermore, microparticles serve as cell-cell messengers by transfer of biological information to target cells in pathophysiological settings and have proven to be prominent biomarkers for health and physiology assessments for both diagnostic and risk stratification purposes. This review describes the mechanisms of microparticles formation, release and clearance, and their detection by currently available and applicable methods. It also discusses the role of microparticles in the development of cardiovascular diseases, as well as their role as biomarkers and cell effectors in the cardiovascular system.","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115282864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pulmonary arterial hypertension (PAH) is a serious complication of congenital heart disease, causing an increase in morbidity and mortality. The progressive and irreversible pulmonary vascular disease is more often the consequence of a significant, uncorrected, left-to-right shunt. The rise in pulmonary vascular resistance may lead to the reversal of the shunt and cyanosis, condition known as Eisenmenger syndrome. The management of this population is challenging and requires specific expertise both for diagnosis and follow-up. The progress in the understanding of the underlying pathophysiology of this condition has promoted recent pharmacological trials. New therapeutic options are now available that could improve the long-term prognosis and the quality of life of these patients, but several controversial points still remain and need to be addressed.
{"title":"Pulmonary hypertension related to congenital heart disease: A comprehensive review","authors":"M. D'alto, A. Merola, K. Dimopoulos","doi":"10.5339/GCSP.2015.42","DOIUrl":"https://doi.org/10.5339/GCSP.2015.42","url":null,"abstract":"Pulmonary arterial hypertension (PAH) is a serious complication of congenital heart disease, causing an increase in morbidity and mortality. The progressive and irreversible pulmonary vascular disease is more often the consequence of a significant, uncorrected, left-to-right shunt. The rise in pulmonary vascular resistance may lead to the reversal of the shunt and cyanosis, condition known as Eisenmenger syndrome. The management of this population is challenging and requires specific expertise both for diagnosis and follow-up. The progress in the understanding of the underlying pathophysiology of this condition has promoted recent pharmacological trials. New therapeutic options are now available that could improve the long-term prognosis and the quality of life of these patients, but several controversial points still remain and need to be addressed.","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2015-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122543460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Torii, X. Xu, I. El-Hamamsy, R. Mohiaddin, M. Yacoub
The aortic valve and root perform extremely sophisticated functions that are critically dependent on their topology as well as the structure of their component parts at tissue, cellular and molecular levels . Each of these components is capable of changing its size and shape during different phases of the cardiac cycle . Computational biomechanics offers unique opportunities to study many of these functions in humans. Rapid progress in this field has resulted in the accumulation of a large amount of knowledge relating to this topic. We here describe the application of biomechanics to the study of the aortic root in health and disease as well as following different types of valve preserving and aortic root replacement using biological valves.
{"title":"Computational biomechanics of the aortic root","authors":"R. Torii, X. Xu, I. El-Hamamsy, R. Mohiaddin, M. Yacoub","doi":"10.5339/AHCSPS.2011.16","DOIUrl":"https://doi.org/10.5339/AHCSPS.2011.16","url":null,"abstract":"The aortic valve and root perform extremely sophisticated functions that are critically dependent on their topology as well as the structure of their component parts at tissue, cellular and molecular levels . Each of these components is capable of changing its size and shape during different phases of the cardiac cycle . Computational biomechanics offers unique opportunities to study many of these functions in humans. Rapid progress in this field has resulted in the accumulation of a large amount of knowledge relating to this topic. We here describe the application of biomechanics to the study of the aortic root in health and disease as well as following different types of valve preserving and aortic root replacement using biological valves.","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133731047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In managing the patient with valvular heart disease (VHD), three major issues must be addressed: (1) assessment of the severity of disease, (2) the effect the disease is having or is likely to have on the patient and his/her cardiovascular system, and (3) the timing and type of intervention to be used to correct the lesion. Existing guidelines are helpful in addressing these tenets in many cases, often using quantifiable parameters to aid the clinician in making key clinical decisions. Many times these guidelines allow the physician and patient to arrive easily at a management strategy. However, in other cases it may take every piece of available data to develop a management plan that is still only a best guess at the proper course to take. Overall, the indications for intervention in VHD are straightforward: valvotomy (in mitral stenosis), or valve repair or valve replacement is indicated when severe VHD causes symptoms or cardiac dysfunction. In some cases, low-risk intervention such as mitral valve repair may be undertaken in the absence of symptoms or dysfunction when it seems inevitable that deterioration will occur because of markedly severe disease. These assessments are rarely made using one test and usually require the integration of all the clinical acumen that can be summoned to address the issues above. The following will summarize the general approach to the assessment of VHD severity, impact, and timing of intervention, with attention paid to the specifics of each individual disease.
{"title":"Assessment of the patient with valvular heart disease: An integrative approach","authors":"B. Carabello","doi":"10.5339/AHCSPS.2011.15","DOIUrl":"https://doi.org/10.5339/AHCSPS.2011.15","url":null,"abstract":"In managing the patient with valvular heart disease (VHD), three major issues must be addressed: (1) assessment of the severity of disease, (2) the effect the disease is having or is likely to have on the patient and his/her cardiovascular system, and (3) the timing and type of intervention to be used to correct the lesion. Existing guidelines are helpful in addressing these tenets in many cases, often using quantifiable parameters to aid the clinician in making key clinical decisions. Many times these guidelines allow the physician and patient to arrive easily at a management strategy. However, in other cases it may take every piece of available data to develop a management plan that is still only a best guess at the proper course to take. Overall, the indications for intervention in VHD are straightforward: valvotomy (in mitral stenosis), or valve repair or valve replacement is indicated when severe VHD causes symptoms or cardiac dysfunction. In some cases, low-risk intervention such as mitral valve repair may be undertaken in the absence of symptoms or dysfunction when it seems inevitable that deterioration will occur because of markedly severe disease. These assessments are rarely made using one test and usually require the integration of all the clinical acumen that can be summoned to address the issues above. The following will summarize the general approach to the assessment of VHD severity, impact, and timing of intervention, with attention paid to the specifics of each individual disease.","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131670222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
تركز اهتمام الدراسات خلال السنوات الأخيرة على قياس النتائج السريرية في مجال جراحة القلب. وبالرغم من أن الأسلوب المحلي لجمع البيانات قديم منذ وجود جراحة القلب إلا أن هناك إدخال تدريجي لقواعد البيانات الموحدة وأنظمة جمع البيانات المحلية والدولية، مما أدى إلى استحداث أنظمة تقييم مستندة إلى تكنولوجيا المعلومات وأبرز الإصدارات حول التوجهات والنتائج. وقد حققت الأنظمة التي تبنت بفاعلية جمع البيانات وتحليلها وتقييمها نتائج ممتازة وأفضل بكثير من الأنظمة التي لم تطبق ذلك. ويضفي تغير العالم المستمر، بفضل تكنولوجيا المعلومات وشبكات التواصل الاجتماعي، انعكاسات كبيرة على جميع مناحي الحياة بما في ذلك قطاع البيع بالتجزئة وعلم الاجتماع وعلم السياسة وبطبيعة الحال الرعاية الصحية. وأحد الجوانب الهامة لذلك التغيير الثقافي هو زيادة الشفافية داخل المجتمع، وتجلى ذلك في المملكة المتحدة عندما كشف الستار عن الفضائح الكبرى حول نفقات أعضاء البرلمان وقوانين الخصوصية واعتراض الرسائل الهاتفية بشكل غير قانوني. أما السبب الرئيسي وراء إحداث طفرة في تقديم الرعاية الصحية وقوانينها في المملكة المتحدة فقد سبق ذلك بقليل حيث تزامن مع فضيحة أحدا...
{"title":"Improving cardiac surgical practice through outcomes analysis","authors":"B. Bridgewater, B. Keogh","doi":"10.5339/AHCSPS.2011.13","DOIUrl":"https://doi.org/10.5339/AHCSPS.2011.13","url":null,"abstract":"تركز اهتمام الدراسات خلال السنوات الأخيرة على قياس النتائج السريرية في مجال جراحة القلب. وبالرغم من أن الأسلوب المحلي لجمع البيانات قديم منذ وجود جراحة القلب إلا أن هناك إدخال تدريجي لقواعد البيانات الموحدة وأنظمة جمع البيانات المحلية والدولية، مما أدى إلى استحداث أنظمة تقييم مستندة إلى تكنولوجيا المعلومات وأبرز الإصدارات حول التوجهات والنتائج. وقد حققت الأنظمة التي تبنت بفاعلية جمع البيانات وتحليلها وتقييمها نتائج ممتازة وأفضل بكثير من الأنظمة التي لم تطبق ذلك. ويضفي تغير العالم المستمر، بفضل تكنولوجيا المعلومات وشبكات التواصل الاجتماعي، انعكاسات كبيرة على جميع مناحي الحياة بما في ذلك قطاع البيع بالتجزئة وعلم الاجتماع وعلم السياسة وبطبيعة الحال الرعاية الصحية. وأحد الجوانب الهامة لذلك التغيير الثقافي هو زيادة الشفافية داخل المجتمع، وتجلى ذلك في المملكة المتحدة عندما كشف الستار عن الفضائح الكبرى حول نفقات أعضاء البرلمان وقوانين الخصوصية واعتراض الرسائل الهاتفية بشكل غير قانوني. أما السبب الرئيسي وراء إحداث طفرة في تقديم الرعاية الصحية وقوانينها في المملكة المتحدة فقد سبق ذلك بقليل حيث تزامن مع فضيحة أحدا...","PeriodicalId":416388,"journal":{"name":"Global Cardiology Science and Practice","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2011-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133048448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：